The European Aids Clinical Society guideline (not yet adjusted to the new nomenclature) recommends screening for NAFLD in PHIV with obesity, metabolic syndrome, persistent ALT elevation, and exposure to d-drugs [44]. Here, GPT is linked to metabolic syndrome.